Learn More
A live attenuated influenza vaccine (LAIV) is currently approved in the United States for the prevention of influenza in individuals 2-49 years of age. This article summarizes the available data describing the safety and efficacy of LAIV for the prevention of influenza in both children and adults. LAIV is administered as an intranasal spray and has been(More)
Development of live attenuated influenza vaccines (LAIV) against avian strains with pandemic potential is an important public-health strategy. Either 1 or 2 10(7)-TCID(50) doses of H9N2 LAIV A/chicken/Hong Kong/G9/97 were administered intranasally to 50 adults in isolation; 41 participants were H9N2 seronegative, 24 of whom received 2 doses. The vaccine was(More)
W e write this note to clarify the article " Live Attenuated Influenza Vaccine Enhances Colonization of Streptococcus pneu-moniae and Staphylococcus aureus in Mice " by Mina et al. (1) in order that patients or clinicians not misinterpret the study's clinical relevance. Mina et al. described interactions between a novel live attenuated influenza virus(More)
  • 1